Efbemalenograstim Alfa

Summary

Efbemalenograstim Alfa (CHEMBL4297950) is an approved protein (ATC L03AA18); indicated across 4 conditions including neutropenia and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AA18
• Indications: 4 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297950
Name	Efbemalenograstim Alfa
Type	Protein
Max phase	4
ATC	L03AA18

Also known as: Benegrastim, Efbemalenograstim alfa, Efbemalenograstim alfa-vuxw, F-627, F627, Rh g-csf fc fusion protein f-627, Ryzneuta, EFBEMALENOGRASTIM ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neutropenia	4	MONDO:0001475	MONDO:0001475
neoplasm	4	MONDO:0005070	EFO:0000616
breast neoplasm	3	MONDO:0021100	MONDO:0007254

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02872103	PHASE3	COMPLETED	Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
NCT03252431	PHASE3	COMPLETED	Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
NCT04174599	PHASE3	COMPLETED	Study to Compare the Efficacy and Safety of F-627 and GRAN®
NCT06251947	PHASE2	RECRUITING	Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
NCT01648322	PHASE2	COMPLETED	Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
NCT02521441	PHASE2	COMPLETED	A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
NCT02522234	PHASE1/PHASE2	COMPLETED	A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
NCT02527746	PHASE1	COMPLETED	Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).